Dengue Clinical Trial
Official title:
Immunogenicity and Safety of a Booster Injection of DTaP-IPV//Hib (Pentaxim™) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in Mexico
The aim of the study was to assess whether the second CYD dengue vaccination could be administered concomitantly with the booster vaccination of a pediatric combination vaccine (Pentaxim™) during the same day visit but in 2 different sites of administration. Primary Objective: - To demonstrate the non-inferiority of the antibody response against all antigens (diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b (Hib)) in participants receiving one booster dose of Pentaxim™ vaccine administered concomitantly with the second dose of CYD dengue vaccine compared to participants receiving one booster dose of Pentaxim™ vaccine administered concomitantly with placebo. Secondary Objectives: - To describe the safety of Pentaxim™ vaccine administered concomitantly with the second dose of CYD dengue vaccine, or administered concomitantly with placebo. - To describe the safety of the CYD dengue vaccine after the second dose of CYD dengue vaccine administered concomitantly with Pentaxim™ vaccine (at Visit 05) or administered alone (at Visit 06). - To describe the safety of the CYD dengue vaccine in all participants after each dose. - To describe the antibody response to each dengue virus serotype (post-Dose 2 and post-Dose 3) after the second dose of CYD dengue vaccine administered concomitantly with Pentaxim vaccine (at Visit 05) or administered alone (at Visit 06). - To describe the antibody response to each dengue virus serotype post-Dose 2 and post-Dose 3.
Participants required 8 or 9 clinic visits and received a total of 7 injections. The dengue post-vaccinal viremia was assessed at Visit 2 from a subset of toddlers. The dengue immunogenicity was assessed 28 days after CYD dengue dose 2 and dose 3 from a subset of toddlers. Participants were followed-up for safety after each vaccine dose and for 6 months after the last dengue vaccination. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05321264 -
Educational Intervention to Promote Control Behaviors and Prevention of Dengue
|
N/A | |
| Completed |
NCT01436396 -
Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers
|
Phase 3 | |
| Completed |
NCT01391819 -
Study to Evaluate the Incidence, Clinical Characteristics and Economic Burden of Dengue in Brazilian Children
|
N/A | |
| Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
| Completed |
NCT02833584 -
Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults
|
N/A | |
| Completed |
NCT02433652 -
Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
|
Phase 1 | |
| Enrolling by invitation |
NCT02016027 -
Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter
|
Phase 1 | |
| Completed |
NCT01477671 -
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
|
N/A | |
| Recruiting |
NCT00377754 -
Prospective Study of Infant Dengue
|
N/A | |
| Recruiting |
NCT05919277 -
A Dengue Sero-prevalence Study in the Metropolitan Area of Buenos Aires
|
||
| Recruiting |
NCT04582474 -
Demonstration of an Electronic Clinical Decision Support Module for Dengue in Burkina Faso
|
N/A | |
| Completed |
NCT01983553 -
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
|
||
| Completed |
NCT03803618 -
Dengue Effectiveness Study in the Philippines
|
||
| Active, not recruiting |
NCT05967455 -
Homologous Re-infection With Dengue 1 or Dengue 3
|
Phase 1 | |
| Completed |
NCT03631719 -
Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
|
||
| Recruiting |
NCT02606019 -
The Use of Biomarkers in Predicting Dengue Outcome
|
N/A | |
| Completed |
NCT02372175 -
Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain
|
Phase 1 | |
| Active, not recruiting |
NCT01696422 -
Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine
|
Phase 2 | |
| Completed |
NCT00993447 -
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
|
Phase 2 | |
| Completed |
NCT00375726 -
Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults
|
Phase 1 |